AMBRISENTAN TEVA 5 mg, film-coated tablet 30 tablets
Active ingredients: Ambrisentan
Commercialized according to BDPMANSM noticeDispensing in France: Prescription only
Film-coated tablet30 tabletsorale
Supply disruption
Package details
Original BDPM fields are shown in French.
- Official name
- AMBRISENTAN TEVA 5 mg, comprimé pelliculé
- Pharmaceutical form
- comprimé pelliculé
- Route of administration
- orale
- Presentation description
- 30 plaquette(s) PVC PVDC papier polytéréphtalate (PET) aluminium de 1 comprimé(s)
- Marketing authorisation holder
- TEVA (PAYS-BAS)
- Reimbursement according to BDPM
- —
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 15 Feb 2021
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Prescribed by a hospital doctor
- Prescribed by specialists only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
68371574CIP73019991CIP133400930199916Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| AMBRISENTANcomprimé | 5 mg · un comprimé | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.